Compare MSM & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSM | CRNX |
|---|---|---|
| Founded | 1941 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 3.9B |
| IPO Year | 1996 | 2018 |
| Metric | MSM | CRNX |
|---|---|---|
| Price | $106.66 | $36.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $96.20 | $76.75 |
| AVG Volume (30 Days) | 630.1K | ★ 1.3M |
| Earning Date | 04-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $3,363,817,000.00 | $1,039,000.00 |
| Revenue This Year | $5.82 | $720.10 |
| Revenue Next Year | $5.26 | $184.67 |
| P/E Ratio | $62.53 | ★ N/A |
| Revenue Growth | ★ 4.99 | N/A |
| 52 Week Low | $78.80 | $25.83 |
| 52 Week High | $108.77 | $57.99 |
| Indicator | MSM | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 63.48 | 45.79 |
| Support Level | $82.74 | $33.19 |
| Resistance Level | $108.77 | $37.23 |
| Average True Range (ATR) | 2.77 | 2.27 |
| MACD | -0.25 | -0.24 |
| Stochastic Oscillator | 76.04 | 29.50 |
Founded in 1941, MSC Industrial Direct originally manufactured and sold cutting tools to metalworking shops in New York. Through a series of acquisitions and organic expansions, MSC has grown into an industrial distribution powerhouse with a focus on specialized metalworking products and services. The firm also distributes a wide breadth of maintenance, repair, and operations supplies. MSC primarily operates in North America, where it derives over 95% of its revenue.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.